Study of thiotepa, pirtobrutinib, and sintilimab for CNS lymphoma
Part of Blood & lymphatic, Brain & nervous system, Cancer clinical trials.
This trial tests a combination of three drugs for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment, or for those who cannot take standard chemotherapy. The goal is to see if this new combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have CNS lymphoma (in the brain or spinal cord) that has come back or not responded, or you cannot take standard chemotherapy with methotrexate.
- You are 18 or older and have a performance status of at least 40 (you are up and about more than half the day).
- Your organs (kidneys, liver, bone marrow) are working well enough as shown by blood tests.
- You can have MRI or CT scans and are willing to have a lumbar puncture (spinal tap).
- You can swallow pills and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (pirtobrutinib) combined with standard chemotherapy and immunotherapy for people with a fast-growing lymphoma that has spread to the brain or spinal cord. The goal is to see if this combination can more effectively treat the lymphoma in these hard-to-reach areas.
This trial tests a combination of two drugs, epcoritamab and ibrutinib, for people whose lymphoma has come back or not responded to treatment and has spread to the brain or spinal cord. The goal is to see if this combination can help control the disease.
This trial tests a combination of drugs (golcadomide, pemetrexed, rituximab, and dexamethasone) for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
This Phase 2 trial studies a combination of anti-cancer medicines to treat lymphoma that is only in the brain/spinal fluid (central nervous system, or CNS), especially when it has come back or not responded. If you qualify, you may benefit from improved tumor control and possibly better symptom control.
This trial tests whether adding an immunotherapy drug to standard chemotherapy helps people with newly diagnosed primary central nervous system lymphoma (a rare brain cancer) live longer without the disease getting worse. It compares the combination to chemotherapy alone.
Hear when a new Sintilimab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.